Market Cap 1.80B
Revenue (ttm) 169.12M
Net Income (ttm) -48.83M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 95.76
Profit Margin -28.87%
Debt to Equity Ratio 0.00
Volume 3,547,500
Avg Vol 2,590,288
Day's Range N/A - N/A
Shares Out 97.10M
Stochastic %K 98%
Beta 1.46
Analysts Sell
Price Target $20.83

Company Profile

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is the LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of cataplexy or excessive daytime sleepiness in patients seven years of age and older with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 a...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 353 1 901 5201
Address:
10 Earlsfort Terrace, Dublin, Ireland
Otus
Otus Oct. 24 at 7:18 PM
$AVDL take a look at CGEN. Everest,Larry and myself own shares. Clinical stage bio has deals with Astra Zeneca and Gilead.
0 · Reply
AnthonySaba79
AnthonySaba79 Oct. 24 at 5:48 PM
$AVDL wtf man
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 24 at 1:18 PM
Enter: $AVDL NOV 21 2025 $20 CALLS Buy in Price: $0.10 - $0.10 Take Profit: $0.19 Stop Bleeding: $0.09 ROI Potential: 91% https://moneygroup.us/
1 · Reply
JarvisFlow
JarvisFlow Oct. 23 at 9:52 PM
Leerink Partners has updated their rating for Avadel Pharmaceuticals ( $AVDL ) to Market Perform with a price target of 18.5.
0 · Reply
ZacksResearch
ZacksResearch Oct. 23 at 3:12 PM
$ALKS to acquire $AVDL in a $2.1B deal — is this a game-changer for ALKS? 🚀 🔹 38% premium to AVDL's 3-month average price 🔹 Lumryz sales up nearly 76% in the first six months of 2025, poised for robust growth 🔹 Strategic entry into the sleep medicine market Discover what this acquisition means for Alkermes' future 👉 https://www.zacks.com/stock/news/2775426/alks-to-enter-sleep-disorder-market-with-21b-avadel-acquisition?cid=sm-stocktwits-2-2775426-body-17298&ADID=SYND_STOCKTWITS_TWEET_2_2775426_BODY_17298
0 · Reply
RunnerSignals
RunnerSignals Oct. 23 at 2:45 PM
🔥52-Week High Breakout Squad $VTYX $NOK $VALE $WBD $AVDL just smashed fresh 52-week highs. bulls running wild and charts on fire!
0 · Reply
Ivorthedriver
Ivorthedriver Oct. 23 at 1:43 PM
$AVDL After 24 hr.s mulling this over...this only makes sense if: The coming 1/4ly shows they spit the bed. As in, they can sell Lumryz, but they can't retain users...or some other problem. Or, This is the way they are putting the co. "in play". Both co.s are fully expecting competing offers to come. Has anyone heard about any M&A investment bank hired for advice to get to this point? For either co.? I haven't. Or, Mgmt. and the bd. REALLY ARE this bad at their jobs...I just find that one hard to believe. No one can be. So, I'm prepping for the possibility/probability for another bid. It won't take much Dollars and I have a handsome profit to fund it. And what are our "investment bankers", with their lofty PPS and sales projections, saying about the deal? Anybody hear? Ivorthedriver
0 · Reply
JarvisFlow
JarvisFlow Oct. 23 at 11:57 AM
HC Wainwright & Co. updates rating for Avadel Pharmaceuticals ( $AVDL ) to Neutral, target set at 36 → 20.
0 · Reply
PhotonTraveller
PhotonTraveller Oct. 23 at 11:41 AM
$AVDL This has a long way to go. Lawsuits will bring out why AVDl was forced to take such a bad deal. Institutions who invested in this aren’t gonna let this slide.
1 · Reply
kdawg1
kdawg1 Oct. 22 at 8:56 PM
$AVDL What? Should wait for settlement, then sell out. Not before. We all got screwed over waiting this long for chump change
1 · Reply
Latest News on AVDL
Alkermes to acquire Avadel for up to $2.1 billion

Oct 22, 2025, 7:11 AM EDT - 3 days ago

Alkermes to acquire Avadel for up to $2.1 billion

ALKS


Avadel: Mispriced Leader In Once-Nightly Sleep Therapies

Sep 30, 2025, 5:20 AM EDT - 25 days ago

Avadel: Mispriced Leader In Once-Nightly Sleep Therapies


Avadel Pharmaceuticals: Moving Nicely Through An 'Inflection Year'

May 15, 2025, 11:43 AM EDT - 5 months ago

Avadel Pharmaceuticals: Moving Nicely Through An 'Inflection Year'


Avadel Pharmaceuticals: Moving To A Speculative Buy

Feb 11, 2025, 6:08 PM EST - 9 months ago

Avadel Pharmaceuticals: Moving To A Speculative Buy


3 Oversold Biotech Names

Jan 13, 2025, 12:56 PM EST - 10 months ago

3 Oversold Biotech Names

FOLD JAZZ VKTX XBI


Avadel Pharmaceuticals: Patient Attrition Weighs On 2025 Outlook

Jan 12, 2025, 3:26 AM EST - 10 months ago

Avadel Pharmaceuticals: Patient Attrition Weighs On 2025 Outlook


US FDA expands approval for Avadel's sleep disorder drug

Oct 17, 2024, 10:03 AM EDT - 1 year ago

US FDA expands approval for Avadel's sleep disorder drug


Otus
Otus Oct. 24 at 7:18 PM
$AVDL take a look at CGEN. Everest,Larry and myself own shares. Clinical stage bio has deals with Astra Zeneca and Gilead.
0 · Reply
AnthonySaba79
AnthonySaba79 Oct. 24 at 5:48 PM
$AVDL wtf man
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 24 at 1:18 PM
Enter: $AVDL NOV 21 2025 $20 CALLS Buy in Price: $0.10 - $0.10 Take Profit: $0.19 Stop Bleeding: $0.09 ROI Potential: 91% https://moneygroup.us/
1 · Reply
JarvisFlow
JarvisFlow Oct. 23 at 9:52 PM
Leerink Partners has updated their rating for Avadel Pharmaceuticals ( $AVDL ) to Market Perform with a price target of 18.5.
0 · Reply
ZacksResearch
ZacksResearch Oct. 23 at 3:12 PM
$ALKS to acquire $AVDL in a $2.1B deal — is this a game-changer for ALKS? 🚀 🔹 38% premium to AVDL's 3-month average price 🔹 Lumryz sales up nearly 76% in the first six months of 2025, poised for robust growth 🔹 Strategic entry into the sleep medicine market Discover what this acquisition means for Alkermes' future 👉 https://www.zacks.com/stock/news/2775426/alks-to-enter-sleep-disorder-market-with-21b-avadel-acquisition?cid=sm-stocktwits-2-2775426-body-17298&ADID=SYND_STOCKTWITS_TWEET_2_2775426_BODY_17298
0 · Reply
RunnerSignals
RunnerSignals Oct. 23 at 2:45 PM
🔥52-Week High Breakout Squad $VTYX $NOK $VALE $WBD $AVDL just smashed fresh 52-week highs. bulls running wild and charts on fire!
0 · Reply
Ivorthedriver
Ivorthedriver Oct. 23 at 1:43 PM
$AVDL After 24 hr.s mulling this over...this only makes sense if: The coming 1/4ly shows they spit the bed. As in, they can sell Lumryz, but they can't retain users...or some other problem. Or, This is the way they are putting the co. "in play". Both co.s are fully expecting competing offers to come. Has anyone heard about any M&A investment bank hired for advice to get to this point? For either co.? I haven't. Or, Mgmt. and the bd. REALLY ARE this bad at their jobs...I just find that one hard to believe. No one can be. So, I'm prepping for the possibility/probability for another bid. It won't take much Dollars and I have a handsome profit to fund it. And what are our "investment bankers", with their lofty PPS and sales projections, saying about the deal? Anybody hear? Ivorthedriver
0 · Reply
JarvisFlow
JarvisFlow Oct. 23 at 11:57 AM
HC Wainwright & Co. updates rating for Avadel Pharmaceuticals ( $AVDL ) to Neutral, target set at 36 → 20.
0 · Reply
PhotonTraveller
PhotonTraveller Oct. 23 at 11:41 AM
$AVDL This has a long way to go. Lawsuits will bring out why AVDl was forced to take such a bad deal. Institutions who invested in this aren’t gonna let this slide.
1 · Reply
kdawg1
kdawg1 Oct. 22 at 8:56 PM
$AVDL What? Should wait for settlement, then sell out. Not before. We all got screwed over waiting this long for chump change
1 · Reply
Witzorwitzout1
Witzorwitzout1 Oct. 22 at 8:15 PM
$AVDL how do shareholders get paid out? 18.50 now and 1.50 next time i see you?
0 · Reply
Fosco_
Fosco_ Oct. 22 at 8:05 PM
$AVDL Almost as predicted, lol ! We did see the insiders rally though. Is the SEC so busy that it can’t investigate on this ?
0 · Reply
Quantumup
Quantumup Oct. 22 at 7:09 PM
RBC Capital⬆️ $ALKS's PT to $ 47 from $45, reiterated at Outperform, and said, Following the announcement of ALKS's intention to acquire $AVDL, we had the chance to catch up with ALKS mgmt. $JAZZ $CNTA $AXSM RBC Capital added: We think the acquisition checks multiple boxes — supporting a key future growth driver with a commercial base of operations, bringing in near-term revenues, and not stretching the balance sheet — and we think bringing in AVDL should strengthen both the near- and mid-term outlook for ALKS. We continue to like the setup into VIBRANCE-2 where we see potential for high efficacy and good tolerability, and with the base business performing well, and a new growth driver added, we would be buyers at these levels; price target to $47.X on model updates as we integrate AVDL.
0 · Reply
KPDOC
KPDOC Oct. 22 at 4:53 PM
0 · Reply
topstockalerts
topstockalerts Oct. 22 at 4:45 PM
$AVDL showing high relative strength..
0 · Reply
Bionick
Bionick Oct. 22 at 4:14 PM
$AVDL was a great ride here AVDL family! I'm a bit sad and a bit happy 😄 Thank you all for sharing your knowledge and good luck
1 · Reply
connor_klein14
connor_klein14 Oct. 22 at 4:08 PM
$AVDL Sometimes a ticker starts acting different. NXXT just flipped phases. Seen this movie before 📈
0 · Reply
JarvisFlow
JarvisFlow Oct. 22 at 4:08 PM
Jefferies has updated their rating for Avadel Pharmaceuticals ( $AVDL ) to Hold with a price target of 20.
0 · Reply
AAAA12345
AAAA12345 Oct. 22 at 4:04 PM
$AVDL The Transaction Agreement contains a customary “fiduciary out” provision that allows the Company, under certain specified circumstances, to furnish information to, or engage in negotiations or discussions with, third parties with respect to a Company Alternative Proposal if the Company complies with certain notice and other requirements (including affording Alkermes certain matching rights) and the Company Board determines in good faith (after consultation with its outside legal counsel and financial advisor(s)) that (x) such Company Alternative Proposal is a Company Superior Proposal (as defined in the Transaction Agreement) and (y) its failure to take such actions would be inconsistent with its fiduciary duties under applicable law. Subject to certain exceptions, the Transaction Agreement also requires the Company to hold an extraordinary general meeting of the Company shareholders and requires the Company Board to recommend approval of the Acquisition to the Company shareholde
1 · Reply
kvkri
kvkri Oct. 22 at 4:01 PM
$AVDL I wish this acquisition deal falls apart asap, way underpriced IMO
0 · Reply
JarvisFlow
JarvisFlow Oct. 22 at 2:38 PM
Needham has updated their rating for Avadel Pharmaceuticals ( $AVDL ) to Hold.
0 · Reply
topstockalerts
topstockalerts Oct. 22 at 2:33 PM
$AVDL strong watch at these levels
0 · Reply